FrancophonIA/ELRC3.0 huggingface dataset:
English: Cytokine release syndrome may be clinically indistinguishable from acute hypersensitivity reactions.
Croatian: Sindrom otpuštanja citokina možda se klinički neće moći razlikovati od akutnih reakcija preosjetljivosti.
English: Consultation with a neurologist should be considered as clinically indicated.
Croatian: valja razmotriti konzultaciju s neurologom.
English: 6.11 years
Croatian: ND 6,11 godina
English: In the maintenance therapy clinical trial, no clinically meaningful differences between the two treatment arms or decreases in total immunoglobulin, IgG, IgM or IgA levels were observed throughout the trial.
Croatian: U kliničkom ispitivanju primjene lijeka za terapiju održavanja ni u jednom trenutku nisu opažene klinički značajne razlike između dviju liječenih skupina kao ni sniženja vrijednosti ukupnog imunoglobulina, IgG, IgM ili IgA.
English: Ritemvia should be used in combination with CHOP chemotherapy.
Croatian: Ritemvia se treba davati u kombinaciji s CHOP kemoterapijom.
English: In these patients the rate of clinically relevant infection while on rituximab was 6.01 per 100 patient years compared to 4.97 per 100 patient years following treatment with the biologic DMARD.
Croatian: U tih je bolesnika stopa klinički značajnih infekcija za vrijeme primjene rituksimaba iznosila 6,01 na 100 bolesnik-godina, u usporedbi s 4,97 na 100 bolesnik-godina nakon primjene biološkog DMARD-a.
English: Subsequent infusions may be administered no sooner than 16 weeks following the previous infusion.
Croatian: Sljedeća se infuzija smije primijeniti najranije 16 tjedana nakon prethodne infuzije.
English: The two adverse events that were reported were flu-like symptoms, with a dose of 1.8 g of rituximab and fatal respiratory failure, with a dose of 2 g of rituximab.
Croatian: Dvije prijavljene nuspojave odnosile su se na simptome nalik gripi pri dozi od 1,8 g rituksimaba te na zatajenje dišnog sustava sa smrtnim ishodom pri dozi od 2 g rituksimaba.
English: A total of 117 patients (88 with GPA, 24 with MPA, and 5 with renal-limited ANCA-associated vasculitis) in disease remission were randomised to receive azathioprine (59 patients) or rituximab (58 patients) in a prospective, multi-center, controlled, open-label study.
Croatian: Ukupno 117 bolesnika (88 bolesnika s GPA-om, 24 s MPA-om i 5 s ANCA vaskulitisom ograničenim na bubrege) kod kojih je bolest bila u remisiji bilo je randomizirano za primanje azatioprina (59 bolesnika) ili lijeka rituksimab (58 bolesnika) u prospektivnom, multicentričnom, kontroliranom, otvorenom ispitivanju.
English: The presence of ADA may be associated with worsening of infusion or allergic reactions after the second infusion of subsequent courses.
Croatian: Prisutnost antitijela na lijek može biti povezana s pojačanim reakcijama na infuziju ili alergijskim reakcijama nakon druge infuzije u daljnjim ciklusima liječenja.
English: Aseptically withdraw the necessary amount of Ritemvia, and dilute to a calculated concentration of 1 to 4 mg/mL rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/mL (0.9%) solution for injection or 5% D-Glucose in water.
Croatian: U aseptičkim uvjetima izvucite potrebnu količinu lijeka Ritemvia i razrijedite do izračunate koncentracije od 1 do 4 mg/ml rituksimaba u vrećici za infuziju koja sadrži sterilnu apirogenu otopinu natrijevog klorida za injekciju od 9 mg/ml (0,9 %) ili 5 %-tnu vodenu otopinu D-glukoze.
English: The reported cases had recognised risk factors for PRES/RPLS, including the patients' underlying disease, hypertension, immunosuppressive therapy and/or chemotherapy.
Croatian: prijavljenim slučajevima postojali su faktori rizika za PRES/RPLS, uključujući osnovnu bolest bolesnika, hipertenziju, terapiju imunosupresivima i/ili kemoterapiju.
English: The prepared Ritemvia solution should be administered as an intravenous infusion through a dedicated line.
Croatian: Pripremljenu otopinu lijeka Ritemvia treba primijeniti intravenskom infuzijom kroz posebnu infuzijsku liniju.
English: In patients with non-Hodgkin's lymphoma receiving rituximab in combination with cytotoxic chemotherapy, cases of hepatitis B reactivation have been reported (see non-Hodgkin's lymphoma).
Croatian: U bolesnika s ne-Hodgkinovim limfomom koji primaju rituksimab u kombinaciji s citotoksičnom kemoterapijom prijavljeni su slučajevi reaktivacije hepatitisa B (vidjeti ne-Hodgkinov limfom).
English: Ritemvia contains the active substance “rituximab”.
Croatian: Ritemvia sadrži djelatnu tvar „rituksimab“.
English: They were characterised by pulmonary events and in some cases included rapid tumour lysis and features of tumour lysis syndrome in addition to fever, chills, rigors, hypotension, urticaria, angioedema and other symptoms (see section 4.8).
Croatian: Kod tih su reakcija bili karakteristični plućni događaji, a u nekim su slučajevima uključivale brzu lizu tumora te obilježja sindroma lize tumora, uz vrućicu, zimicu, tresavicu, hipotenziju, urtikariju, angioedem i druge simptome (vidjeti dio 4.8).
English: Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Croatian: (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
English: Results from three other randomised trials using rituximab in combination with chemotherapy regimen other than CVP (CHOP, MCP, CHVP/Interferon-α) have also demonstrated significant improvements in response rates, time-dependent parameters as well as in overall survival.
Croatian: Rezultati drugih triju randomiziranih ispitivanja u kojima je rituksimab primjenjivan u kombinaciji s kemoterapijskim režimom koji nije bio CVP (CHOP, MCP, CHVP/interferon alfa) također su pokazali značajno poboljšanje stopa odgovora, parametara ovisnih o vremenu te ukupnog preživljenja.
English: This is mostly accounted for by IRRs (most frequent during the first treatment course), RA exacerbation and infections all of which were more frequent in the first 6 months of treatment.
Croatian: Za to su uglavnom zaslužne reakcije povezane s infuzijom (najčešće tijekom prvog ciklusa liječenja), egzacerbacija reumatoidnog artritisa i infekcije jer su se sve one javljale češće tijekom prvih 6 mjeseci liječenja.
English: Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na pakiranju i bočici iza oznake „Rok valjanosti“ ili „EXP“.
English: Toxic Epidermal Necrolysis (Lyell's syndrome) and Stevens-Johnson syndrome, some with fatal outcome, have been reported very rarely.
Croatian: Vrlo su rijetko prijavljeni toksična epidermalna nekroliza (Lyellov sindrom) i Stevens-Johnsonov sindrom, ponekad sa smrtnim ishodom.
English: Rituximab should not be administered to patients with an active, severe infection (e.g. tuberculosis, sepsis and opportunistic infections, see section 4.3).
Croatian: Rituksimaba se ne smije primijeniti bolesnicima s aktivnom teškom infekcijom (npr. tuberkulozom, sepsom i oportunističkim infekcijama, vidjeti dio 4.3).
English: The rate of overall infections and serious infections was not increased after the development of low IgA, IgG or IgM.
Croatian: Stopa svih infekcija i ozbiljnih infekcija nije se povećala nakon nastupa niskih vrijednosti IgA, IgG ili IgM.
English: Subsequent doses of Ritemvia can be infused at an initial rate of 100 mg/h, and increased by 100 mg/h increments at 30 minute intervals, to a maximum of 400 mg/h.
Croatian: Sljedeće doze lijeka Ritemvia mogu se dati početnom brzinom infuzije od 100 mg/sat, a brzina se može povećavati za 100 mg/sat u razmacima od 30 minuta, do najviše 400 mg/sat.
English: In patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis, methylprednisolone given intravenously for 1 to 3 days at a dose of 1000 mg per day is recommended prior to the first infusion of Ritemvia (the last dose of methylprednisolone may be given on the same day as the first infusion of Ritemvia).
Croatian: U bolesnika s granulomatozom s poliangitiisom (Wegenerova granulomatoza) ili mikroskopskim poliangitiisom se prije prve infuzije lijeka Ritemvia preporučuje intravenska primjena metilprednizolona u dozi od 1000 mg na dan tijekom 1 do 3 dana (posljednja doza metilprednizolona može se dati istoga dana kao i prva infuzija lijeka Ritemvia).
English: In patients with non-Hodgkin's lymphoma, premedication with glucocorticoids should be considered if Ritemvia is not given in combination with glucocorticoid-containing chemotherapy.
Croatian: U bolesnika s ne-Hodgkinovim limfomom potrebno je razmotriti premedikaciju glukokortikoidima ako se Ritemvia ne primjenjuje u kombinaciji s kemoterapijom koja sadrži glukokortikoide.
English: Patients who develop severe cytokine release syndrome should have their infusion interrupted immediately (see section 4.2) and should receive aggressive symptomatic treatment.
Croatian: bolesnika u kojih se pojavi teški oblik sindroma otpuštanja citokina mora se odmah prekinuti primjena infuzije (vidjeti dio 4.2) i primijeniti agresivno simptomatsko liječenje.
English: In the maintenance therapy clinical trial, 7/57 (12%) patients in the rituximab arm experienced at least one infusion-related reaction.
Croatian: U kliničkom ispitivanju primjene lijeka za terapiju održavanja 7/57 (12%) bolesnika u skupini liječenoj lijekom rituksimabom imalo je najmanje jednu reakciju povezanu s infuzijom.
English: Adverse drug reactions presented in Table 5 were adverse events which occurred at a rate of ≥ 5% among rituximab-treated PV patients, with a ≥ 2% absolute difference in incidence between the rituximab-treated group and the standard-dose prednisone group up to month 24.
Croatian: Nuspojave navedene u Tablici 5 predstavljaju štetne događaje čija je stopa među bolesnicima s PV-om liječenima lijekom rituksimab iznosila ≥ 5% i za koje je apsolutna razlika u incidenciji između skupine liječene lijekom rituksimab i one liječene standardnom dozom prednizona iznosila ≥ 2% do 24. mjeseca.
English: Rituximab is associated with infusion-related reactions, which may be related to release of cytokines and/or other chemical mediators.
Croatian: Rituksimaba se povezuje s reakcijama na infuziju, koje mogu biti posljedica otpuštanja citokina i/ili drugih kemijskih medijatora.
English: 6 observed mainly in patients with prior cardiac condition and/or cardiotoxic chemotherapy and were mostly associated with infusion-related reactions
Croatian: 6 Primijećeno najčešće u bolesnika s prethodnim srčanim poremećajima i/ili kardiotoksičnom kemoterapijom i najčešće vezano uz reakcije povezane s infuzijom.
English: Following induction of remission with other standard of care immunosuppressants, Ritemvia maintenance treatment should be initiated during the 4 week period that follows disease remission.
Croatian: Nakon poticanja remisije primjenom drugih imunosupresiva koji se koriste u standardnom liječenju, terapiju održavanja lijekom Ritemvia treba započeti tijekom 4-tjednog razdoblja nakon nastupa remisije bolesti.
English: • you have ever had heart problems (such as angina, palpitations or heart failure) or breathing problems.
Croatian: • ako ste ikada imali srčane tegobe (poput angine pektoris, osjećaja lupanja srca ili zatajenja srca)
English: • fever, cough, sore throat, burning pain when passing urine or feeling weak or generally unwell
Croatian: • vrućicu, kašalj, grlobolju, žareću bol prilikom mokrenja, slabost ili opće loše osjećanje
English: These patients were treated either with rituximab monotherapy (as induction treatment or maintenance treatment following induction treatment) or in combination with chemotherapy.
Croatian: Ti su bolesnici liječeni rituksimabom u monoterapiji (početno liječenje ili terapija održavanja nakon početnog liječenja) ili u kombinaciji s kemoterapijom.
English: Reactions attributed to hypersensitivity have been reported less frequently than those attributed to cytokine release.
Croatian: Reakcije koje se pripisuju preosjetljivosti prijavljene su rjeđe od onih vezanih uz otpuštanje citokina.
English: Talk to your doctor, pharmacist or nurse before you are given Ritemvia if:
Croatian: Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primite lijek Ritemvia:
English: Rituximab maintenance treatment significantly prolonged median PFS in patients responding to CHOP induction therapy (median PFS 37.5 months vs. 11.6 months, p< 0.0001) as well as in those responding to R-CHOP induction (median PFS 51.9 months vs. 22.1 months, p=0.0071).
Croatian: Terapija održavanja rituksimabom značajno je produljila medijan PFS-a u bolesnika koji su odgovorili na uvodnu terapiju CHOP-om (medijan PFS-a 37,5 mjeseci u odnosu na 11,6 mjeseci, p < 0,0001) kao i u onih koji su odgovorili na indukciju R-CHOP-om (medijan PFS-a 51,9 mjeseci u odnosu na 22,1 mjesec, p = 0,0071).
English: serum sickness-like reaction
Croatian: reakcija nalik serumskoj bolesti
English: Concentrate for solution for infusion 500 mg / 50 mL
Croatian: Koncentrat za otopinu za infuziju 500 mg/50 ml
English: Vaccination should be completed at least 4 weeks prior to first administration of rituximab.
Croatian: Cijepljenje treba dovršiti najmanje 4 tjedna prije prve primjene lijeka rituksimaba.
English: The majority of patients (81%) showed signs of B
Croatian: Većina je bolesnika (81 %)
English: Rituximab mean clearance and volume of distribution were 0.313 L/day (range, 0.116 to 0.726 L/day) and 4.50 L (range 2.25 to 7.39 L) respectively.
Croatian: Srednja vrijednost klirensa rituksimaba iznosila je 0,313 l/dan (raspon: 0,116 do 0,726 l/dan), a volumena raspodjele 4,50 l (raspon: 2,25 do 7,39 l).
English: Cases of hepatitis B reactivation, have been reported, the majority of which were in patients receiving rituximab in combination with cytotoxic chemotherapy.
Croatian: Prijavljeni su slučajevi reaktivacije hepatitisa B, većina njih u bolesnika koji su primali rituksimab u kombinaciji s citotoksičnom kemoterapijom.
English: Consideration should be given to the use of a reduced infusion rate for the first infusion in these patients or a split dosing over two days during the first cycle and any subsequent cycles if the lymphocyte count is still > 25 x 109/L.
Croatian: U tih bolesnika treba razmotriti smanjenje brzine infuzije pri primjeni prve doze ili raspodjelu doziranja u dva dana tijekom prvog ciklusa, ali i bilo kojeg sljedećeg ciklusa ako je broj limfocita i dalje > 25 x 109/l.
English: 18-months p = 0.016
Croatian: 18 mjeseci p = 0,016
English: Table 6 Summary of key results from four phase III randomised studies evaluating the benefit of rituximab with different chemotherapy regimens in follicular lymphoma
Croatian: Tablica 6 Sažetak najvažnijih rezultata četiriju randomiziranih ispitivanja faze III u kojima se procjenjivala korist liječenja folikularnog limfoma rituksimabom u kombinaciji s različitim režimima kemoterapije
English: This is equivalent to 2.6% of the recommended maximum daily dietary intake of sodium for an adult.
Croatian: To odgovara 2,6% preporučenog maksimalnog dnevnog unosa soli za odraslu osobu.
English: Due to the long retention time of rituximab in B cell depleted patients, women of childbearing potential should use effective contraceptive methods during and for 12 months following treatment with rituximab.
Croatian: Zbog dugog vremena zadržavanja rituksimaba u bolesnika s deplecijom B-stanica, žene reproduktivne dobi moraju koristiti učinkovite metode kontracepcije tijekom i 12 mjeseci nakon terapije lijekom rituksimaba.
English: This set of reactions which includes syndrome of cytokine release, tumour lysis syndrome and anaphylactic and hypersensitivity reactions are described below.
Croatian: Ovaj skup reakcija, koje uključuju sindrom otpuštanja citokina, sindrom lize tumora te anafilaktičke reakcije i reakcije preosjetljivosti, opisuje se u nastavku.
English: The highest intravenous dose of rituximab tested in humans to date is 5000 mg (2250 mg/m2), tested in a dose escalation study in patients with CLL.
Croatian: Najviša do sada ispitivana intravenska doza rituksimaba u ljudi iznosi 5000 mg (2250 mg/m2), a testirana je u sklopu ispitivanja postupnog povećanja doze u bolesnika s KLL-om.
English: Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes.
Croatian: Rituksimab se veže isključivo za transmembranski antigen CD20, neglikozilirani fosfoprotein smješten na pre-B i zrelim B-limfocitima.
English: The proportion of patients with IgG levels below the LLN was about 60% in the rituximab group throughout the 2 year treatment period, while it decreased in the observation group (36% after 2 years).
Croatian: Udio bolesnika s razinom IgG-a ispod donje granice normalnih vrijednosti bio je oko 60 % u skupini koja je primala rituksimab tijekom cjelokupnog dvogodišnjeg razdoblja liječenja, dok se u opservacijskoj skupini smanjio (36 % nakon 2 godine).
English: What Ritemvia is used for
Croatian: Za što se Ritemvia koristi
English: +myocardial infarction4 and 6, arrhythmia, +atrial fibrillation,
Croatian: +infarkt miokarda4 i 6, aritmija, +fibrilacija atrija, tahikardija,
English: Ritemvia should be administered on day 1 of each chemotherapy cycle, after intravenous administration of the glucocorticoid component of the chemotherapy if applicable.
Croatian: Ritemvia se treba primijeniti prvog dana svakog kemoterapijskog ciklusa, nakon intravenske primjene glukokortikoidne komponente kemoterapije, ako je liječenje obuhvaća.
English: Concentrate for solution for infusion 100 mg / 10 mL
Croatian: Koncentrat za otopinu za infuziju 100 mg/10 ml
English: Blood and lymphatic system disorders neutropenia1
Croatian: Poremećaji krvi i limfnog sustava neutropenija1
English: This is equivalent to 13.2% of the recommended maximum daily dietary intake of sodium for an adult.
Croatian: To odgovara 13,2% preporučenog maksimalnog dnevnog unosa soli za odraslu osobu.
English: late neutropenia3
Croatian: odgođena neutropenija3
English: Observation N=513
Croatian: N=513
English: If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given Ritemvia.
Croatian: Ako se nešto od gore navedenoga odnosi na Vas (ili niste sigurni), obratite se svom liječniku,
English: In patients with rheumatoid arthritis, 283 patients received subsequent therapy with a biologic DMARD following rituximab.
Croatian: Nakon primjene rituksimaba 283 bolesnika s reumatoidnim artritisom nastavila su terapiju nekim biološkim DMARD-om.
English: The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes and the Fc domain can recruit immune effector functions to mediate B cell lysis.
Croatian: Fab domena rituksimaba veže se na antigen CD20 na B-limfocitima, a Fc domena može pokrenuti funkcije imunog efektora na posredovanje lize B-stanica.
English: The analysis of overall survival showed a significant benefit of R-FC treatment over FC chemotherapy alone (p=0.0319, log-rank test) (Table 10a).
Croatian: Analiza ukupnog preživljenja pokazala je značajnu korist R-FC terapije u odnosu na primjenu samo FC kemoterapije (p = 0,0319, log-rang test) (Tablica 10a).
English: Log-rank p value
Croatian: log-rang p-vrijednost
English: A total of 19/34 (56%) patients with PV, who were treated with rituximab, tested positive for ADA antibodies by 18 months.
Croatian: Ukupno 19/34 (56%) bolesnika s PV-om liječenih lijekom rituksimab bilo je pozitivno na antitijela na lijek u 18. mjesecu.
English: Before giving a subsequent course of rituximab treatment, patients should be re-evaluated for any potential risk for infections.
Croatian: Prije primjene sljedećeg ciklusa lijeka rituksimaba treba ponovno procijeniti stanje bolesnika kako bi se utvrdio potencijalni rizik od infekcija.
English: The primary objective for the study was complete remission (complete epithelialisation and absence of new and/or established lesions) at month 24 without the use of prednisone therapy for two months or more (CRoff for ≥ 2 months).
Croatian: Primarni cilj ispitivanja bila je potpuna remisija (potpuna epitelizacija i odsutnost novih i/ili otprije postojećih lezija) u 24. mjesecu bez primjene prednizona tijekom dva ili više mjeseci (potpuna remisija bez primjene kortikosteroida tijekom ≥ 2 mjeseca).
English: 4 see also section infusion-related reactions below.
Croatian: 4 Vidjeti i dio o reakcijama povezanima s infuzijom u nastavku.
English: Using a cox regression analysis, the risk of experiencing progressive disease or death was reduced by 61% with rituximab maintenance treatment when compared to observation (95% CI; 45%-72%).
Croatian: Coxova regresijska analiza pokazala je da terapija održavanja rituksimabom smanjuje rizik od progresije bolesti i smrti za 61 % u usporedbi s opservacijskom skupinom (95 % CI 45 % - 72 %).
English: Significant improvement in health related quality of life was also demonstrated with significant improvement in both the physical health score (PHS) and mental health score (MHS) of the SF-36.
Croatian: Značajno poboljšanje kvalitete života vezane uz zdravlje također je potvrđeno značajnim poboljšanjem rezultata fizičkog zdravlja (engl.
English: Neither age, sex, lymphoma grade, initial diagnosis, presence nor absence of bulky disease, normal or high LDH nor presence of extranodal disease had a statistically significant effect (Fisher's exact test) on response to rituximab.
Croatian: Dob, spol, stupanj zloćudnosti limfoma, početna dijagnoza, prisutnost ili odsutnost proširenosti tumora, normalan ili povišeni LDH i ekstranodalna bolest nisu (prema Fisherovom testu vjerojatnosti) statistički značajno utjecali na odgovor na liječenje rituksimabom.
English: Initial treatment, weekly for 8 doses
Croatian: Početno liječenje, jedanput tjedno tijekom 8 tjedana
English: The overall safety profile of rituximab in non-Hodgkin's lymphoma and CLL is based on data from patients from clinical trials and from post-marketing surveillance.
Croatian: Ukupan sigurnosni profil rituksimaba u liječenju ne-Hodgkinova limfoma i KLL-a temelji se na podacima o bolesnicima koji su sudjelovali u kliničkim ispitivanjima i praćenju nakon stavljanja lijeka u promet.
English: In Trial 1, conducted in patients with inadequate response or intolerance to one or more TNF inhibitor therapies, receiving rituximab in combination with methotrexate demonstrated significantly less radiographic progression than patients originally receiving methotrexate alone at 56 weeks.
Croatian: U Ispitivanju 1, provedenom u bolesnika koji nisu zadovoljavajuće odgovorili na jednu ili više terapija TNF-inhibitorima ili ih nisu dobro podnosili, bolest je, sudeći prema radiološkim znakovima, nakon 56 tjedana napredovala znatno manje u bolesnika liječenih rituksimabom u kombinaciji s metotreksatom nego u bolesnika koji su prvotno primali samo metotreksat.
English: During this time, 81% of patients, from the original placebo group received rituximab between weeks 24 and 56, under an open label extension study protocol.
Croatian: Tijekom tog razdoblja 81 % bolesnika iz skupine koja je prvotno primala placebo je, prema protokolu za otvoreno produljenje ispitivanja, od 24. do 56. tjedna primalo rituksimab.
English: Concomitant/sequential use of other DMARDs in rheumatoid arthritis The concomitant use of rituximab and anti-rheumatic therapies other than those specified under the rheumatoid arthritis indication and posology is not recommended.
Croatian: Istodobna/sekvencijska primjena drugih DMARD-a u liječenju reumatoidnog artritisa Istodobna primjena lijeka rituksimaba i antireumatskih lijekova koji nisu navedeni u poglavljima o indikaciji i doziranju za reumatoidni artritis se ne preporučuje.